Absstract of: EP3834847A1

Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient.

Absstract of: WO2020030654A1

The present invention relates to polypeptides self-assembling into nanoparticles. In particular, the invention relates to a polypeptide comprising an amino acid sequence I (SEQ ID NO: 1), a nucleic acid sequence encoding said polypeptide, a nanoparticle comprising at least one polypeptide of the invention, a complex comprising said nanoparticle and one or more cargo molecules, and a method for transfecting a cell with said complex.

Absstract of: WO2021109714A1

Disclosed are Millettia speciosa polysaccharides, a preparation method therefor and an application thereof in antibacterial aspects. The method comprises the following steps: (1) cleaning, slicing, drying, smashing and sieving Millettia speciosa root pieces, and then performing hot water reflux extraction to obtain a crude extract of Millettia speciosa polysaccharides; (2) depigmenting the crude extract of the Millettia speciosa polysaccharides by using macroporous resin, removing residual protein by using a Sevag reagent, and then performing alcohol precipitation to obtain crude Millettia speciosa polysaccharides; (3) adding the crude Millettia speciosa polysaccharides to water to prepare a crude Millettia speciosa polysaccharide solution, and then adding same to a DEAE-52 cellulose anion exchange column, eluting by using distilled water and 0.2 mol/L of a NaCl solution successively, and collecting eluates separately to obtain Millettia speciosa polysaccharides MSCP1 and MSCP2. The Millettia speciosa polysaccharides prepared in the present invention have a certain inhibitory effect on Gram-negative bacteria, especially Escherichia coli and Salmonella. Therefore, the Millettia speciosa polysaccharides can be used to develop antibacterial materials or antibacterial agents.

Absstract of: WO2021109924A1

The present invention relates to the use of myricetin in the preparation of a salmonella type III secretion system inhibitor. Human cervical cancer cells (HeLa) are used as the infection carrier. In vivo and in vitro experiments confirm that myricetin inhibits the function of a type III secretion system, and so has a significant inhibitory effect on salmonella infections. Compared with the action mechanism of traditional antibiotics in directly killing salmonella, the traditional Chinese medicine compound myricetin can directly inhibit the function of salmonella type III secretion system, thereby exerting an anti-infection effect, which gives bacteria a small selective pressure and does not easily induce the emergence of bacteria drug resistance, and has the characteristics of wide sources, low cost and high cure rate.

Absstract of: CA2804709A1

The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue, wherein the condition characterized by inflammation is not a cancer. In embodiments of the invention, a cancer is situated in the specific organ or tissue.

Absstract of: US2021169972A1

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

Absstract of: US2021162034A1

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Absstract of: US2021162033A1

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be 5 used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

Absstract of: WO2021102546A1

The present invention relates to a qualitative method and kit for the colorimetric detection of Salmonella for surfaces based on gold nanoparticles and aptamers, and an Aptasensor comprising same for a novel qualitative method of colorimetric detection of Salmonella contamination in surface samples using gold nanoparticles and aptamers. In particular, the invention provides highly sensitive and specific bifunctional oligonucleotide probes that can be used for detecting Salmonella in samples containing interferents, such as food supply chain surface samples. The invention also anticipates a detection kit and a method involving same for detecting Salmonella. The invention also provides two sequences of probes functionalized with the thiol group for detecting Salmonella contamination. In another important aspect of the invention, an aptasensor is provided containing a gold nanoparticle and a main aptamer which is bound by means of probes complementary to the sequence of the main aptamer. Detection is carried out in surface samples based on a change in colour.

Absstract of: EP3827825A1

The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as an antibacterial or antibioticagainst Staphylococcus, Escherichia, Streptococcus, Klebsiella, Mycobacterium, Pseudomonas, Clostridium, Acinetobacter, Enterococcus, Pasteurella Bacillus anthracis. Listeria monocytogenes, Corynebacterium diphtheriae, Salmonella, Shigella, Moraxella, Helicobacter, Legionella, Vibrio, Rickettsia, Neisseria, Actinobacter, is disclosed.

Absstract of: CN106103489A

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD 8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin- derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capabl e of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1 ) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

Absstract of: US2021155677A1

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface. Microbe-targeting molecules and/or substrates can be regenerated after use by washing with a low pH buffer or buffer in which calcium is insoluble.

Absstract of: WO2021098989A1

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gramnegative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

Absstract of: AU2021202654A1

Abstract The present invention relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bac-teria of the genus Salmonella or Shigella and variants, fragments and immunmodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunmodulatory domains thereof, for delivering cargo molecules into eukaryotic cells.

Absstract of: US2021155942A1

The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of heterologous proteins into eukaryotic cells.

Absstract of: US2021157250A1

Provided are toners and combinations of toners that demonstrate excellent color and are Ames test negative in both Salmonella typhimurium strains TA98 and TA100.

Absstract of: EP3825422A2

A method for the simultaneous detection of a combination of multiple Gram-positive bacteria and/or Gram-negative bacteria in a sample, the method comprising: providing DNA extracted from the sample; preparing a reaction mixture containing the DNA, one or more pairs of oligonucleotide primers having a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 11, SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 16 and SEQ ID NO: 17 and combinations of same, and one or more oligonucleotide probes having a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 and combinations of same; amplifying the DNA included in the reaction mixture, by means real-time polymerase chain reaction; and simultaneously determining the presence or absence of Gram-positive bacteria and/or Gram-negative bacteria in the sample. The method can be used to identify any combination of three species of Gram-positive bacteria (Listeria ssp., Listeria monocytogenes and Staphylococcus aureus) and three species of Gram-negative bacteria (Escherichia coli spp., Escherichia coli O157:H7 and Salmonella spp.).

Absstract of: GB2589159A

Provided herein are methods and apparatus for the identification of pathogenic and non-pathogenic microorganisms in food and environmental samples. The disclosure solves existing challenges encountered in identifying food borne pathogens, including pathogens of the Salmonella, Campylobacter, Listeria, and Escherichia genera in a timely and efficient manner. The disclosure also provides methods for differentiating a transient versus a resident pathogen, correlating presence of non-pathogenic with pathogenic microorganisms, distinguishing live versus dead microorganisms by sequencing.

Absstract of: US2021147491A1

A method for increase the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.

Absstract of: US2021145954A1

The present invention relates to Salmonella mutant strains and their use as a vaccine for preventing Salmonella infection, in particular in eggs.

Absstract of: WO2020014543A2

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin- and/or pagP -. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd -, purI - and msbB -. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment or tumor-resident immune cells and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

Absstract of: WO2019226978A1

The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.

Absstract of: US2021138059A1

The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia Coli, Vibrio Cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.

Absstract of: US2015072338A1

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

Absstract of: WO2021086085A1

The present invention relates to a tumor-targeting Salmonella gallinarum strain and the use thereof. The tumor-targeting Salmonella gallinarum strain has excellent tumor proliferation inhibitory activity and enables tumor-specific targeting, and thus can be utilized for treatment and imaging of tumors without any side effects.